 Connection
Marc Bonaca to Ischemia
This is a "connection" page, showing publications Marc Bonaca has written about Ischemia.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
4.650 |
|
|
|
-
Hess CN, Debus ES, Nehler MR, Anand SS, Patel MR, Szarek M, Capell WH, Hsia J, Beckman JA, Brodmann M, Diaz R, Habertheuer P, Leeper NJ, Powell RJ, Sillesen H, Muehlhofer E, Berkowitz SD, Haskell LP, Bauersachs RM, Bonaca MP. Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD. Circulation. 2021 12 07; 144(23):1831-1841.
Score: 0.624
-
Desai U, Kharat A, Hess CN, Milentijevic D, Lalibert? F, Zuckerman P, Benson J, Lefebvre P, Hiatt WR, Bonaca MP. Incidence of Major Atherothrombotic Vascular Events among Patients with Peripheral Artery Disease after Revascularization. Ann Vasc Surg. 2021 Aug; 75:217-226.
Score: 0.601
-
Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, Fanelli F, Capell WH, Diao L, Jaeger N, Hess CN, Pap AF, Kittelson JM, Gudz I, M?ty?s L, Krievins DK, Diaz R, Brodmann M, Muehlhofer E, Haskell LP, Berkowitz SD, Hiatt WR. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med. 2020 05 21; 382(21):1994-2004.
Score: 0.561
-
Bonaca MP, Gutierrez JA, Creager MA, Scirica BM, Olin J, Murphy SA, Braunwald E, Morrow DA. Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2?P-TIMI 50). Circulation. 2016 Mar 08; 133(10):997-1005.
Score: 0.420
-
Bonaca MP, Scirica BM, Creager MA, Olin J, Bounameaux H, Dellborg M, Lamp JM, Murphy SA, Braunwald E, Morrow DA. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. Circulation. 2013 Apr 09; 127(14):1522-9, 1529e1-6.
Score: 0.344
-
Bonaca MP, Les?n E, Giannitsis E, Hedberg J, Jernberg T, Lambrelli D, Duong M, Maggioni AP, Ariza-Sol? A, Ten Berg J, Storey RF. Characteristics and outcomes in patients with a prior myocardial infarction treated with extended dual antiplatelet therapy with ticagrelor 60 mg: findings from ALETHEIA, a multi-country observational study. Eur Heart J Cardiovasc Pharmacother. 2023 Dec 14; 9(8):701-708.
Score: 0.181
-
Bonaca MP, Hogan SE. Tradeoffs in Approach to PAD?Revascularization: Shared Decision Making in the Spotlight. J Am Coll Cardiol. 2023 01 31; 81(4):371-373.
Score: 0.171
-
Bonaca MP, Im K, Magnani G, Bansilal S, Dellborg M, Storey RF, Bhatt DL, Steg PG, Cohen M, Johanson P, Braunwald E, Sabatine MS. Patient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI 54. Eur Heart J. 2022 12 21; 43(48):5037-5044.
Score: 0.169
-
Govsyeyev N, Nehler M, Conte MS, Debus S, Chung J, Dorigo W, Gudz I, Krievins D, Mills J, Moll F, Norgren L, Piffaretti G, Powell R, Szalay D, Sillesen H, Wohlauer M, Szarek M, Bauersachs RM, Anand SS, Patel MR, Capell WH, Jaeger N, Hess CN, Muehlhofer E, Haskell LP, Berkowitz SD, Bonaca MP. Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits. J Vasc Surg. 2023 04; 77(4):1107-1118.e2.
Score: 0.169
-
Bonaca MP, Szarek M, Debus ES, Nehler MR, Patel MR, Anand SS, Muehlhofer E, Berkowitz SD, Haskell LP, Bauersachs RM. Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a "CASPAR like" outcome from VOYAGER PAD. Clin Cardiol. 2022 Dec; 45(12):1143-1146.
Score: 0.167
-
Anand SS, Hiatt W, Dyal L, Bauersachs R, Berkowitz SD, Branch KRH, Debus S, Fox KAA, Liang Y, Muehlhofer E, Nehler M, Haskell LP, Patel M, Szarek M, Yusuf S, Eikelboom J, Bonaca MP. Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. Eur J Prev Cardiol. 2022 05 05; 29(5):e181-e189.
Score: 0.162
-
Gilchrist IC, Morrow DA, Creager MA, Olin JW, Scirica BM, Goodrich EL, Bonaca MP. Efficacy and Safety of Vorapaxar by Intensity of Background Lipid-Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P-TIMI 50 Trial. J Am Heart Assoc. 2021 10 19; 10(20):e021412.
Score: 0.156
-
Bauersachs RM, Szarek M, Brodmann M, Gudz I, Debus ES, Nehler MR, Anand SS, Patel MR, Hess CN, Capell WH, Rogers K, Muehlhofer E, Haskell LP, Berkowitz SD, Hiatt WR, Bonaca MP. Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD?Trial. J Am Coll Cardiol. 2021 07 27; 78(4):317-326.
Score: 0.152
-
Capell WH, Barnathan ES, Piazza G, Spyropoulos AC, Hsia J, Bull S, Lipardi C, Sugarmann C, Suh E, Rao JP, Hiatt WR, Bonaca MP. Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study. Am Heart J. 2021 05; 235:12-23.
Score: 0.149
-
Bonaca MP, Hess CN, Hiatt WR. The Pathobiology of Acute Limb Ischemic?Events and Stent Failure in Peripheral Artery Disease: A Step in the Right Direction. JACC Cardiovasc Interv. 2020 02 24; 13(4):428-430.
Score: 0.139
-
Creager MA, Bonaca MP. Pathology of Arterial Disease in Limb?Loss: The Clot Thickens. J Am Coll Cardiol. 2018 10 30; 72(18):2164-2165.
Score: 0.127
-
Bonaca MP, Bhatt DL, Storey RF, Steg PG, Cohen M, Kuder J, Goodrich E, Nicolau JC, Parkhomenko A, L?pez-Send?n J, Dellborg M, Dalby A, ?pinar J, Aylward P, Corbal?n R, Abola MTB, Jensen EC, Held P, Braunwald E, Sabatine MS. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2016 Jun 14; 67(23):2719-2728.
Score: 0.106
-
Varcoe RL, DeRubertis BG, Kolluri R, Krishnan P, Metzger DC, Bonaca MP, Shishehbor MH, Holden AH, Bajakian DR, Garcia LA, Kum SWC, Rundback J, Armstrong E, Lee JK, Khatib Y, Weinberg I, Garcia-Garcia HM, Ruster K, Teraphongphom NT, Zheng Y, Wang J, Jones-McMeans JM, Parikh SA. Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease. N Engl J Med. 2024 Jan 04; 390(1):9-19.
Score: 0.045
-
Rymer J, Anand SS, Sebastian Debus E, Haskell LP, Hess CN, Jones WS, Muehlhofer E, Berkowitz SD, Bauersachs RM, Bonaca MP, Patel MR. Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD. Circulation. 2023 12 12; 148(24):1919-1928.
Score: 0.045
-
Cheng HS, P?rez-Cremades D, Zhuang R, Jamaiyar A, Wu W, Chen J, Tzani A, Stone L, Plutzky J, Ryan TE, Goodney PP, Creager MA, Sabatine MS, Bonaca MP, Feinberg MW. Impaired angiogenesis in diabetic critical limb ischemia is mediated by a miR-130b/INHBA signaling axis. JCI Insight. 2023 05 22; 8(10).
Score: 0.044
-
Cheng HS, Zhuang R, P?rez-Cremades D, Chen J, Jamaiyar A, Wu W, Sausen G, Tzani A, Plutzky J, Henao-Mejia J, Goodney PP, Creager MA, Sabatine MS, Bonaca MP, Feinberg MW. A miRNA/CXCR4 signaling axis impairs monopoiesis and angiogenesis in diabetic critical limb ischemia. JCI Insight. 2023 04 10; 8(7).
Score: 0.043
-
McCoy MG, Jamaiyar A, Sausen G, Cheng HS, P?rez-Cremades D, Zhuang R, Chen J, Goodney PP, Creager MA, Sabatine MS, Bonaca MP, Feinberg MW. MicroRNA-375 repression of Kruppel-like factor 5 improves angiogenesis in diabetic critical limb ischemia. Angiogenesis. 2023 02; 26(1):107-127.
Score: 0.042
-
Beckman JA, Duncan MS, Damrauer SM, Wells QS, Barnett JV, Wasserman DH, Bedimo RJ, Butt AA, Marconi VC, Sico JJ, Tindle HA, Bonaca MP, Aday AW, Freiberg MS. Microvascular Disease, Peripheral Artery Disease, and Amputation. Circulation. 2019 08 06; 140(6):449-458.
Score: 0.033
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|